Development of nuclide targeted matrix metalloproteinase inhibitors in atherosclerotic plaque imaging
10.3760/cma.j.issn.2095-2848.2019.01.014
- VernacularTitle:核素标记基质金属蛋白酶抑制剂在动脉粥样硬化斑块显像中的研究进展
- Author:
Yan HU
1
;
Dengfeng CHENG
;
Hongcheng SHI
Author Information
1. 复旦大学附属中山医院核医学科、上海市影像医学研究所、复旦大学核医学研究所 200032
- Keywords:
Plaque,atherosclerotic;
Radionuclide imaging;
Matrix metalloproteinases;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(1):45-48
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerotic vulnerable plaques may cause acute cardiovascular events.Matrix metalloproteinase (MMP) plays an important role in the pathological process of high-risk plaques.It degrades the extracellular matrix of atherosclerotic plaque,thus making the fibrous cap thinner and the plaque more vulnerable,which lead to rupture.MMP inhibitors (MMPI) can specially bind MMP and inhibit its activity.Taking MMP as the target,nuclear medical imaging can identify and evaluate the unstable plaque in molecular level,and can also be used to explore the biological characteristics of plaque,as well as to monitor drug efficiency.This review summarizes the development of nuclide targeted MMPI in atherosclerotic plaque imaging.
